Modulation of hair growth

1 . A method for modulating the growth, development, or maintenance of hair or hair follicles in a vertebrate animal subject, said method comprising administering to said subject an RNAi agent, wherein said RNAi agent delays, represses or otherwise reduces the expression of a hair associated genetic target in the vertebrate animal subject.

2 . The method of claim 1 , wherein the RNAi agent comprises a nucleotide sequence which is at least 70% identical to at least part of a nucleotide sequence comprising a hair associated genetic target, or a derivative, ortholog, or homolog thereof.

3 . The method of claim 1 , wherein the hair associated genetic target comprises a nucleotide sequence encoding 5α-dihydrotestosterone (DHT) receptor, steroid 5α-reductase polypeptide 1, or steroid 5α-reductase polypeptide 2.

4 . The method of claim 1 , wherein the hair associated genetic target comprises a nucleotide sequence encoding the hairless (hr), the lanceolate hair (lah) locus, Dsg4 (Desmoglein 4), Shh (Sonic hedgehog), Vegf, Cd34 (Cd34 antigen), S100, Ibd2 (Ibd2 helix-loop-helix antagonist), Ibd4, Peg3 (Paternally expressed gene 3), Fzd2 (Frizzled 2), Dkk3 (Dickkopf homolog 3), Sfrp1 (Secreted Frizzled Related Protein 1), Dab2 (Disabled homolog 2), Cktsflb1 (Gremlin, cysteine knot superfamily 1, BMP antagonist 1), Fgfr1 (Fibroblast growth factor receptor 1), Fgt1 (Fibroblast growth factor 1), Gpr49 (G-protein-coupled receptor 49), Igfbp5 (Insulin-linke growth factor binding protein 5), Myoc (Trabecular meshwork induced glucocorticoid protein), Itm2a (Integral membrane protein 2A), Eps8 (Epidermal growth factor receptor pathway substrate 8), Fyn (Fyn proto-oncogene), Col6a1 (Procollagen, type IV, alpha 1), Tnc (Tenascin C), Krt2-6a (Keratin complex 2, basic, gene 6a), Potassium channel subfamily K encoding sequences, Skd3 (Suppressor of K+ transport defect 3), Clic4 (Chloride intracellular channel 4), Col18al (Endostatin, alpha 1 (XVIII) collagen), Gna14 (Guanine nucleotide binding protein), Ly6 (Lymphocyte antigen 6 complex), Bmp4 (Bone morphogenetic protein 4), II1r2 (Interleukin 1 receptor, type II), Wnt3a (Wingless-related MMTV integration site 3A), II12rb2 (Interleukin 12 receptor, beta 2), Wnt10a (Wingless-related MMTV integration site 10a), Ifngr2 (Interferon-gamma receptor precursor), Fgfbp1 (Fibroblast growth factor binding protein 1), Klf5 (Kruppel-like factor 5), Gata3 (GATA binding protein 3), Retinoic acid stimulated basic helix-loop-helix protein encoding sequences, Mki67 (antigen identified by monoclonal antibody Ki-67), Cks2 (CDC28 protein kinase regulatory subunit 2), Ccng2 (Cyclin G2), or Prc1 (Protein regulator of cytokinesis 1).

5 . The method of claim 1 , wherein administering an RNAi agent comprises administering a ddRNAi expression vector comprising one or more ddRNAi expression cassettes that effect RNAi-mediated silencing of one or more hair associated genetic targets.

6 . The method of claim 5 , wherein the ddRNAi expression vector comprises at least two ddRNAi expression cassettes.

7 . The method of claim 5 , wherein the ddRNAi expression vector is administered to the vertebrate animal subject by a viral delivery system.

8 . The method of claim 7 , wherein the viral delivery system is an Adeno-Associated Virus (AAV) derived delivery system.

9 . A ddRNAi expression vector comprising one or more ddRNAi expression cassettes, wherein each ddRNAi expression cassette, once expressed in a host cell effects transcription of an RNAi agent which effects RNAi-mediated silencing of a hair associated genetic target.

10 . A pharmaceutical composition comprising:

a ddRNAi expression vector comprising one or more ddRNAi expression cassettes, wherein each ddRNAi expression cassette, once expressed in a host cell effects transcription of an RNAi agent which effects RNAi-mediated silencing of a hair associated genetic target; and

a pharmaceutically acceptable carrier or diluent.